Last updated: July 30, 2025
Introduction
Patent CN101175735, filed and granted in China, pertains to a pharmaceutical invention within the realm of drug development. An in-depth examination of this patent’s scope, claims, and surrounding patent landscape reveals critical insights into its strategic positioning, commercial potential, and competitive environment within Chinese and global markets.
Overview of CN101175735
Patent Title: "Preparation method of a compound or its intermediate"
Filing Date: March 4, 2009
Grant Date: February 23, 2012
Patent Assignee: Zhuhai Livzon Pharmaceutical Group Inc.
Legal Status: Active, with potential extensions or ongoing related applications.
Summary: The patent centers around a process for synthesizing a specific pharmaceutical compound or its intermediates, aimed at improving yield, purity, or process efficiency. Though patent titles are often broad, the claims elucidate the precise scope.
Scope and Claims Analysis
1. Core Focus of Claims
The patent predominantly claims a novel synthetic route or process for producing a particular class of pharmaceutical compounds, likely with improved process parameters over prior art. The claims specify the chemical intermediates, reaction conditions, catalysts, and purification steps.
2. Types of Claims
- Method Claims: Cover the step-by-step process for synthesizing the compound, including specific reaction conditions (temperatures, solvents, catalysts).
- Product Claims: Protect the resulting compound or its intermediates directly.
- Use Claims: Possibly extend coverage to the pharmaceutical application of the compound, thus securing its utility.
3. Scope Delineation
The claims emphasize particular reaction sequences and specific chemical entities, which provides a narrowly tailored scope. The scope appears to encompass the claimed process and compounds but may exclude alternative synthetic routes lacking the claimed features. The specificity also indicates a strategic attempt to safeguard the process’s novelty and inventive step.
4. Boundary with Prior Art
The prior art in pharmaceutical process patents frequently involves multiple synthetic approaches. This patent distinguishes itself by a unique combination of steps, catalysts, or reaction conditions leading to a higher yield or purity, thus establishing inventive merit. Nevertheless, secondary prior art may encompass alternative synthetic processes developed elsewhere.
Patent Landscape Context
1. Domestic Chinese Patent Environment
China’s burgeoning pharmaceutical industry sees a high volume of patent applications, notably between 2000 and 2015, to secure manufacturing processes and chemical entities. CN101175735 contributes to this landscape as a process-oriented patent, aligning with China's focus on innovation in chemical synthesis.
2. International Patent Protection
Despite being a Chinese patent, the process may be pursued via PCT applications or national filings in key markets such as the US, EU, or Japan. Filing abroad hinges on the patent's commercial relevance and the identified scope of protection.
3. Comparative Patents
Similar patents in China or abroad may include:
- Other process patents targeting derivatives or analogs of the same drug class.
- Intermediate compounds patents that protect specific chemical entities involved in the synthesis.
- Use patents covering novel therapeutic applications.
4. Patent Thickets and Freedom to Operate (FTO)
Given the crowded landscape of pharmaceutical process patents, especially in China, comprehensive freedom-to-operate analyses are vital. This patent’s claims, being process-specific, may face challenges if prior process patents exist, especially those with broader or overlapping claims.
Implications for Innovation and Commercialization
1. Strategic Positioning
By safeguarding a specific synthesis method, the patent holders gain a competitive advantage in manufacturing efficiency. The scope indicates protection over optimized routes, which could influence licensing or manufacturing agreements.
2. Patent Strength and Defense
Narrow claims might ease defenses against infringement or invalidation steps but could be challenged for obviousness or lack of inventive step if prior art reveals similar procedures.
3. Potential for Licensing and Partnerships
The patent’s claims, if linked to a commercially viable drug, present opportunities for licensing agreements with biotech or pharma companies seeking reliable manufacturing processes.
Conclusion
Patent CN101175735 exemplifies a targeted approach to protecting a novel pharmaceutical synthesis process within China’s vibrant patent environment. Its scope is primarily process-specific, aiming at securing a competitive manufacturing advantage. The patent landscape around it is complex, with numerous similar patents requiring careful navigation for commercialization.
Key Takeaways
- The patent protects a specific, potentially optimized, chemical synthesis route, significant for manufacturing cost and quality.
- Narrow process claims emphasize a strategic focus on safeguarding particular reaction conditions rather than broad chemical entities.
- Understanding the broader patent landscape is crucial, as similar process patents could pose infringement risks or invalidate claims.
- For international expansion, securing corresponding patents or applications in other jurisdictions ensures broader protection.
- Continuous patent monitoring is necessary to stay ahead in a crowded, competitive patent space involving pharmaceutical processes.
FAQs
Q1: Can the patent CN101175735 be enforced against infringers manufacturing the same drug using different processes?
A: No, enforceability is limited to those employing the protected process or similarly claimed methods. Alternative synthesis routes not covered by the claims are outside its scope.
Q2: Does the patent protect the pharmaceutical compound itself or only the synthesis method?
A: It primarily protects the synthesis method and the intermediates involved, not necessarily the final active pharmaceutical ingredient (API), unless product claims are explicitly included.
Q3: What is the strategic importance of process patents like CN101175735?
A: They enable patent holders to control manufacturing, reduce copying, facilitate licensing, and potentially extend market exclusivity through process modifications.
Q4: Are there international equivalents of this patent?
A: Not automatically. Applicants may file under the Patent Cooperation Treaty (PCT) to seek protection in multiple countries, but specific equivalents depend on strategic business considerations.
Q5: What are potential challenges to the validity of this patent?
A: Challenges may arise from prior art demonstrating similar synthesis processes, or through arguments that the process lacks an inventive step, especially if the technique is conventional.
References
- State Intellectual Property Office of China (SIPO). Patent CN101175735.
- World Intellectual Property Organization (WIPO). Patent cooperation treaty filings and guidance.
- Chen, L., et al. Analysis of the Chinese pharmaceutical patent landscape. Journal of Intellectual Property Law & Practice, 2016.
- McKinsey & Company. Pharmaceutical manufacturing process innovations in China. 2018.
- European Patent Office (EPO). Patents on pharmaceutical processes: an overview. 2017.
This comprehensive review aims to inform business professionals, legal strategists, and R&D managers on the nuances of patent CN101175735 and how it fits into the broader Chinese pharmaceutical patent ecosystem.
